How big was multidistrict litigation this year? Really big. Stupendously big. The cases were so phenomenally large that they generated significant political interest, with the Obama administration and various government oversight departments getting actively involved. And, for once, a pharmaceutical manufacturer was not the primary target.

Consider what the year presented: